The milestone comes just weeks after the launch of the BD-Ebov study and marks the first time the ChAdOx1 BDBV vaccine has been administered to humans.
The ChAdOx1 BDBV vaccine was developed by scientists at the University of Oxford’s Oxford Vaccine Group and Pandemic Sciences Institute using the same vaccine technology as the Oxford/AstraZeneca COVID-19 vaccine, which is estimated to have saved around six million lives during its first year of use.
The speed of the programme has been enabled through a truly collaborative and global approach and is built on decades of vaccine manufacturing capabilities at the University's Clinical BioManufacturing Facility (CBF) and the Serum Institute of India (SII). SII manufactured ChAdOx1 BDBV vaccine in a record time and stockpiled 620,000 doses.
The study team will continue recruiting and vaccinating volunteers over the coming weeks while monitoring participants to assess both safety and immune responses generated by the vaccine.
Read the full story on the University of Oxford website.